Benign prostatic hyperplasia pipeline review, h1 2014


Published on

This report provides comprehensive information on the therapeutic development for Benign Prostatic Hyperplasia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases.

Published in: Business, Health & Medicine
  • Be the first to comment

  • Be the first to like this

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide

Benign prostatic hyperplasia pipeline review, h1 2014

  1. 1. Benign Prostatic Hyperplasia - Pipeline Review, H1 2014 This report provides comprehensive information on the therapeutic development for Benign Prostatic Hyperplasia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Benign Prostatic Hyperplasia and special features on late-stage and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope The report provides a snapshot of the global therapeutic landscape of Benign Prostatic Hyperplasia The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities The report reviews key players involved in the therapeutics development for Benign Prostatic Hyperplasia and enlists all their major and minor projects The report summarizes all the dormant and discontinued pipeline projects A review of the Benign Prostatic Hyperplasia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages A detailed assessment of monotherapy and combination therapy pipeline projects Coverage of the Benign Prostatic Hyperplasia pipeline on the basis of target, MoA, route of administration and molecule type Latest news and deals relating related to pipeline products Reasons to buy Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage Develop strategic initiatives by understanding the focus areas of leading companies Identify and understand important and diverse types of therapeutics under development for Benign Prostatic Hyperplasia Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline Devise corrective measures for pipeline projects by understanding Benign Prostatic Hyperplasia pipeline depth and focus of Indication therapeutics Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline table Of Contents table Of Contents 2 list Of Tables 7 list Of Figures 8 introduction 9 global Markets Direct Report Coverage 9 benign Prostatic Hyperplasia Overview 10 therapeutics Development 11 pipeline Products For Benign Prostatic Hyperplasia Overview 11 pipeline Products For Benign Prostatic Hyperplasia Comparative Analysis 12 benign Prostatic Hyperplasia Therapeutics Under Development By Companies 13 benign Prostatic Hyperplasia Therapeutics Under Investigation By Universities/institutes 16 benign Prostatic Hyperplasia Pipeline Products Glance 17 late Stage Products 17 clinical Stage Products 18 early Stage Products 19 unknown Stage Products 20 benign Prostatic Hyperplasia Products Under Development By Companies 21 benign Prostatic Hyperplasia Products Under Investigation By Universities/institutes 22 benign Prostatic Hyperplasia Companies Involved In Therapeutics Development 23 eli Lilly And Company 23 euroscreen S.a. 24 aphios Corporation 25 astellas Pharma Inc. 26 chong Kun Dang Pharmaceutical Corp. 27 chugai Pharmaceutical Co., Ltd. 28 sk Chemicals Co., Ltd. 29 addex Therapeutics 30 aeterna Zentaris Inc. 31 intelgenx Corp. 32 kaken Pharmaceutical Co., Ltd. 33 karo Bio Ab 34 Benign Prostatic Hyperplasia - Pipeline Review, H1 2014
  2. 2. nymox Pharmaceutical Corporation 35 quest Pharmatech Inc. 36 sophiris Bio, Inc. 37 androscience Corporation 38 novalead Pharma Pvt. Ltd. 39 amvac Ag 40 kael-gemvax Co., Ltd. 41 ausio Pharmaceuticals, Llc 42 hanmi Pharmaceuticals, Co. Ltd. 43 som Biotech Sl 44 curadis Gmbh 45 balonco Gmbh 46 benign Prostatic Hyperplasia Therapeutics Assessment 47 assessment By Monotherapy Products 47 assessment By Combination Products 48 assessment By Target 49 assessment By Mechanism Of Action 52 assessment By Route Of Administration 55 assessment By Molecule Type 57 drug Profiles 59 tadalafil - Drug Profile 59 product Description 59 mechanism Of Action 59 r&d Progress 59 nx-1207 - Drug Profile 61 product Description 61 mechanism Of Action 61 r&d Progress 61 topsalysin - Drug Profile 63 product Description 63 mechanism Of Action 63 r&d Progress 63 mcs-2 - Drug Profile 65 product Description 65 mechanism Of Action 65 r&d Progress 65 ozarelix - Drug Profile 67 product Description 67 mechanism Of Action 67 r&d Progress 67 teverelix - Drug Profile 69 product Description 69 mechanism Of Action 69 r&d Progress 69 aus-131 - Drug Profile 71 product Description 71 mechanism Of Action 71 r&d Progress 71 udenafil - Drug Profile 73 product Description 73 mechanism Of Action 73 r&d Progress 73 amv-110 - Drug Profile 75 product Description 75 mechanism Of Action 75 r&d Progress 75 asp-4901 - Drug Profile 76 product Description 76 mechanism Of Action 76 r&d Progress 76 amv-100 - Drug Profile 77 product Description 77 mechanism Of Action 77 r&d Progress 77 asp-0306 - Drug Profile 78 product Description 78 mechanism Of Action 78 r&d Progress 78 Benign Prostatic Hyperplasia - Pipeline Review, H1 2014
  3. 3. asp-6432 - Drug Profile 79 product Description 79 mechanism Of Action 79 r&d Progress 79 ckd-902 - Drug Profile 80 product Description 80 mechanism Of Action 80 r&d Progress 80 adx-68692 - Drug Profile 81 product Description 81 mechanism Of Action 81 r&d Progress 81 sperol - Drug Profile 82 product Description 82 mechanism Of Action 82 r&d Progress 82 tertomotide - Drug Profile 83 product Description 83 mechanism Of Action 83 r&d Progress 83 asc-jm.x2 - Drug Profile 85 product Description 85 mechanism Of Action 85 r&d Progress 85 vldm-01 - Drug Profile 86 product Description 86 mechanism Of Action 86 r&d Progress 86 esn-364 - Drug Profile 87 product Description 87 mechanism Of Action 87 r&d Progress 87 sl-052 - Drug Profile 88 product Description 88 mechanism Of Action 88 r&d Progress 88 estrogen Receptor Program - Drug Profile 90 product Description 90 mechanism Of Action 90 r&d Progress 90 s-40542 - Drug Profile 91 product Description 91 mechanism Of Action 91 r&d Progress 91 nce-403 - Drug Profile 92 product Description 92 mechanism Of Action 92 r&d Progress 92 som-2391 - Drug Profile 93 product Description 93 mechanism Of Action 93 r&d Progress 93 (tamsulosin + Dutasteride) - Drug Profile 94 product Description 94 mechanism Of Action 94 r&d Progress 94 ch-5036249 - Drug Profile 95 product Description 95 mechanism Of Action 95 r&d Progress 95 l1ad3 - Drug Profile 96 product Description 96 mechanism Of Action 96 r&d Progress 96 kisspeptin Peptide Antagonists - Drug Profile 97 product Description 97 mechanism Of Action 97 r&d Progress 97 Benign Prostatic Hyperplasia - Pipeline Review, H1 2014
  4. 4. cr-1493 - Drug Profile 98 product Description 98 mechanism Of Action 98 r&d Progress 98 som-2393 - Drug Profile 99 product Description 99 mechanism Of Action 99 r&d Progress 99 small Molecule To Inhibit Steroidal 5-alpha Reductase For Benign Prostatic Hyperplasia - Drug Profile 100 product Description 100 mechanism Of Action 100 r&d Progress 100 int-0031 - Drug Profile 101 product Description 101 mechanism Of Action 101 r&d Progress 101 benign Prostatic Hyperplasia Recent Pipeline Updates 102 benign Prostatic Hyperplasia Dormant Projects 118 benign Prostatic Hyperplasia Discontinued Products 119 benign Prostatic Hyperplasia Product Development Milestones 120 featured News & Press Releases 120 nov 19, 2013: Cialis (tadalafil) Marks 10 Years Since U.s. Approval 120 nov 11, 2013: Nymox Reports Update And Positive Safety Data For Phase 3 Nx02-0022 Reinjection Study Of Nx-1207 For Bph 121 oct 28, 2013: Sophiris Announces First Patients Dosed In The Plus-1 Phase 3 Trial Of Prx302 For Benign Prostatic Hyperplasia 122 oct 25, 2013: Fda Approves Addition To Cialis Product Label 122 aug 22, 2013: Nymox Reports Positive Results Of Safety Monitoring Committee Review Of Nx02-0018 Phase 3 Trial 124 jul 11, 2013: Nymox Reports Positive Safety Monitoring Committee Results For Pivotal Nx02-0017 Phase 3 Trial 124 jun 19, 2013: Actavis And Kissei Pharma File Lawsuits Against Sandoz And Hetero For Infringement Of Rapaflo Patent 125 may 06, 2013: Nymox Presents Clinical Data On Nx-1207 At American Urological Association Annual Meeting 125 may 03, 2013: Nymox Pharma Completes Patient Enrollment In Final Pivotal Us Phase Iii Bph Study 126 apr 30, 2013: Nymox Pharma Provides Further Information About Upcoming Symposium On Nx-1207 126 appendix 128 methodology 128 coverage 128 secondary Research 128 primary Research 128 expert Panel Validation 128 contact Us 129 disclaimer 129 ResearchMoz( is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price. Contact: M/s Sheela, 90 State Street, Suite 700, Albany NY - 12207 United States Tel: +1-518-618-1030 USA - Canada Toll Free 866-997-4948 Email: Website: Benign Prostatic Hyperplasia - Pipeline Review, H1 2014